Moving beyond constant stimulation to brain-responsive therapy. Clinical evidence driving the next generation of Parkinsonâs treatment.
Clinical Perspective
With Newronika, the clinician isnât just treating a patient â they are finally âvisualizingâ the disease as it unfolds, enabling therapy that responds to the brain, not just a programmerâs estimate.
"With aDBS, we are no longer limited to observing symptoms. For the first time, we can access neural signals associated with a patient's clinical state and enable therapy to adapt in real time. This gives neurologists a new window into the brain activity linked to Parkinson's symptoms, allowing treatment to be personalized according to the patient's changing needs. It fundamentally changes the clinical conversation."
Alberto Priori, MD PhD
Co-Founder & Scientific Advisory Board Chairman, University of Milan
âSwitching from conventional DBS to adaptive DBS brought an additional improvement in my symptoms. I was even able to stop taking my Parkinsonâs medications and leave behind the side effects that came with them. Today, I have regained a life I never thought I would have againâ
Luca
Patient
"Parkinsonâs disease had taken away my ability to walk and to work. Thanks to adaptive DBS, I regained my independence, my confidence, and my life"
Davide
Patient
"Adaptive DBS's ability to respond by synchronizing therapy with symptoms and behavior is opening a new era of personalized treatment for Parkinsonâs disease and other neurological disorders."
Ioannis U. Isaias, MD PhD
Chief Medical Officer, Newronika
Clinical Outcomes
Across 6 completed studies and 50+ patients, Newronikaâs adaptive DBS delivers clinically significant improvements.
Waking hours with good symptom relief
Double-blind crossover study. Chart adapted from Newronika clinical data on file.
Clinical Pipeline & Trials
A decade of iterative clinical work has built a rigorous evidence base â and the most advanced phase is just beginning.
Newronika has successfully concluded first-in-human trials demonstrating safety and efficacy of adaptive DBS across 6 completed studies. Over 50 patients have been implanted, providing the clinical foundation for CE Mark approval under EU MDR.
The ADVENT study is a US FDA pivotal trial designed to support approval of both cDBS and aDBS. Protocol approved March 2026. Enrolling across US &Â EU.
Beyond Parkinson's, Newronika is pursuing feasibility work across additional neurological and neuropsychiatric indications, leveraging the same closed-loop platform and the unique biomarker capabilities of WebBioBankâą.
The first FDA pivotal trial for both conventional and adaptive DBS in Parkinsonâs disease.
Key Publications & Evidence
Newronikaâs clinical work is grounded in published, peer-reviewed research from leading neurological journals.
Links are representative. Full publication list and DOIs available upon request from clinical@newronika.com.
Whether youâre a clinician, researcher, investor, or partner â weâd love to hear from you.
